Search

Your search keyword '"Sessa, U."' showing total 7 results
Start Over Author "Sessa, U."
7 results on '"Sessa, U."'

1. CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL

Author

Peluso AL, Seneca E, Cosenza MR, Musella F, Cacciapuoti V, Esposito N, Muccioli Casadei G, Pisano I, De Angelis B, Annunziata M, Sessa U, Nunziata G, Palmieri F, Palmieri R, Danise P, Pezzullo L, Serio B, Esposito MR, Villa MR, Spiezia M, Vallone R, De Falco G, Sica A, Camera A, Iovine M, Svanera L, Soverini S, Martinelli G, Luciano L, QUINTARELLI, CONCETTA, IZZO, BARBARA, PANE, FABRIZIO, Peluso AL, Peluso, Al, Quintarelli, Concetta, Seneca, E, Cosenza, Mr, Musella, F, Cacciapuoti, V, Esposito, N, Izzo, Barbara, Muccioli Casadei, G, Pisano, I, De Angelis, B, Annunziata, M, Sessa, U, Nunziata, G, Palmieri, F, Palmieri, R, Danise, P, Pezzullo, L, Serio, B, Esposito, Mr, Villa, Mr, Spiezia, M, Vallone, R, De Falco, G, Sica, A, Camera, A, Iovine, M, Svanera, L, Soverini, S, Martinelli, G, Luciano, L, and Pane, Fabrizio

Published
2013

2. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib

Author

Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., on behalf of the GIMEMA CML Working Party (Lucarelli, G., Polimeno, G., Ladetto, M., Pini, M., Rupoli, S., Scortechini, A. R., Galieni, P., Bigazzi, C., Cantore, N., Palmieri, F., Specchia, G., Russo, Rossi., Rambaldi, A., Ferrari, M. L., Palandri, F., Luatti, S., Iacobucci, I., Bochicchio, M. T., Apolinari, M., Fogli, M., Cervello, I., Capucci, A., Giuliani, G., Malpignano, A., Girasoli, M., Angelucci, E., Usala, E., De Biasi, E., Tagariello, G., Sartori, R., Di Raimondo, F., Vigneri, P., Molica, S., Lentini, M., Lanza, F., Viganò, C., Grasso, M., Rapezzi, D., Cuneo, A., Ciccone, M., Bosi, A., Gozzini, A., Gobbi, M., Pierri, I., Chianese, R., De Blasio, A., Ciccone, F., Capochiani, E., Pelosini, M., Musolino, C., Russo, S., Cortelezzi, A., Luppi, M., Marasca, R., Pogliani, E. M., Gambacorti-Passerini, C., Luciano, L., Izzo, B., Ferrara, F., Annunziata, M., Mettivier, V., Sessa, U., Latte, G., Noli, D., Rege-Cambrin, G., Fava, C., Semenzato, G., Binotto, G., Fabbiano, F., Turri, D., Siragusa, S., Caracciolo, C., Musso, M., Porretto, F., Cazzola, M., Orlandi, E., Falini, B., Falzetti, F., Visani, G., Isidor, I., Di Bartolomeo, P., Di Lorenzo, R., Vallisa, D., Trabacch, I., Pizzuti, M., Zuffa, E., Salvucci, M., Ronco, F., Lelo, D., Merli, F., Avanzini, P., Tosi, P., Merli, A., Sica, S., Sorà, F., Latagliata, R., De Fabritiis, P., Trawiska, M., Amadori, S., Cantonetti, M., Majolino, I., Pacilli, L., Ronci, B., Cedrone, M., Mengarelli, A., Romano, A., Tafuri, A., Montefusc, O., Iuliano, F., Infusino, S., Dore, F., Fozza, C., Bocchia, M., Defina, M., Liberati, Am., Luzi, D., Boccadoro, M., Ferrero, D., Vitolo, U., Nicolosi, M., Gottardi, M., Calistri, E., Fanin, R., Tiribelli, M., Pizzolo, G., Bonifacio, M., Rodeghiero, F., Di Bona, E. )., Castagnetti, F, Gugliotta, G., Breccia, M., Stagno, F., Iurlo, A., Albano, F., Abruzzese, E., Martino, B., Levato, L., Intermesoli, T., Pregno, P., Rossi, G., Gherlinzoni, F., Leoni, P., Cavazzini, F., Venturi, C., Soverini, S., Testoni, N., Alimena, G., Cavo, M., Martinelli, G., Pane, F., Saglio, G., Rosti, G., Baccarani, M., and on behalf of the GIMEMA CML Working Party [, Palandri F.], Pane, Fabrizio, Gugliotta, G, Breccia, M, Stagno, F, Iurlo, A, Albano, F, Abruzzese, E, Martino, B, Levato, L, Intermesoli, T, Pregno, P, Rossi, G, Gherlinzoni, F, Leoni, P, Cavazzini, F, Venturi, C, Soverini, S, Testoni, N, Alimena, G, Cavo, M, Martinelli, G, Pane, F, Saglio, G, Rosti, G, Baccarani, M, and GAMBACORTI PASSERINI, C

Subjects
DIAGNOSED CHRONIC-PHASE, Oncology, Male, Cancer Research, Time Factors, bcr-abl, Fusion Proteins, bcr-abl, Antineoplastic Agent, Hematology, Anesthesiology and Pain Medicine, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, 80 and over, Cumulative incidence, Young adult, Chronic, Aged, 80 and over, Leukemia, PATIENTS RECEIVING IMATINIB, CHRONIC MYELOGENOUS LEUKEMIA, TYROSINE KINASE INHIBITORS, BCR-ABL1 TRANSCRIPT LEVELS, EARLY MOLECULAR RESPONSE, CML WORKING PARTY, 3-YEAR FOLLOW-UP, EUROPEAN LEUKEMIANET, 400 MG, Myeloid leukemia, Middle Aged, Prognosis, Treatment Outcome, Retreatment, Imatinib Mesylate, Female, Tyrosine kinase, Human, medicine.drug, Adult, medicine.medical_specialty, Time Factor, Adolescent, Prognosi, Protein Kinase Inhibitor, Socio-culturale, Antineoplastic Agents, Treatment results, Follow-Up Studie, Young Adult, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Internal medicine, medicine, Humans, Protein Kinase Inhibitors, Aged, Antineoplastic Combined Chemotherapy Protocol, business.industry, Fusion Proteins, Imatinib, Follow-Up Studies, Surgery, Imatinib mesylate, BCR-ABL Positive, business, Myelogenous
Abstract

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia. The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment optimization. The debate is still heated: some studies have protocol restrictions or limited follow-up; in other studies, some relevant data are missing. The aim of this report is to provide a comprehensive, long-term, intention-to-treat, analysis of 559 newly diagnosed, chronic-phase, patients treated frontline with imatinib. With a minimum follow-up of 66 months, 65% of patients were still on imatinib, 19% were on alternative treatment, 12% died and 4% were lost to follow-up. The prognostic value of BCR-ABL1 ratio at 3 months (⩽10% in 81% of patients) was confirmed. The prognostic value of complete cytogenetic response and major molecular response at 1 year was confirmed. The 6-year overall survival was 89%, but as 50% of deaths occurred in remission, the 6-year cumulative incidence of leukemia-related death was 5%. The long-term outcome of first-line imatinib was excellent, also because of second-line treatment with other TKIs, but all responses and outcomes were inferior in high-risk patients, suggesting that to optimize treatment results, a specific risk-adapted treatment is needed for such patients.

Published
2015

3. CLINICAL RELEVANCE IN CHRONIC MYELOID LEUKEMIA OF DELETION AND INSERTION EVENTS IN THE TYROSINE KYNASE DOMAIN OF BCR-ABL

Author

Peluso AL, Cosenza MR, EspositoN, Muccioli Casadei G, VillaMR, EspositoMR, DaniseP, PezzulloL, MennaG, MettivierV, Sessa U, Pizzuti M, Annunziata M, Spieza M, Serio B, Palmieri F, Vallone R, Martino B, Iovine M, SENECA, ELISA, QUINTARELLI, CONCETTA, MUSELLA, FILOMENA, IZZO, BARBARA, RUSSO, FILIPPO, CAMERA, ANDREA, LUCIANO, LUIGIA, PANE, FABRIZIO, Peluso AL, Peluso, Al, Seneca, Elisa, Cosenza, Mr, Quintarelli, Concetta, Musella, Filomena, Espositon, Muccioli Casadei, G, Izzo, Barbara, Villamr, Espositomr, Danisep, Pezzullol, Mennag, Mettivierv, Sessa, U, Pizzuti, M, Annunziata, M, Spieza, M, Russo, Filippo, Serio, B, Palmieri, F, Vallone, R, Martino, B, Iovine, M, Camera, Andrea, Luciano, Luigia, and Pane, Fabrizio

Published
2012

7. Ruolo del protocollo DVd nella terapia del mieloma

Author

Carbone A, Celentano M, Sica A, Criscuolo C, De Lucia M, Riccardi C, Sessa U, GUASTAFIERRO, Salvatore, Carbone, A, Celentano, M, Sica, A, Criscuolo, C, De Lucia, M, Riccardi, C, Sessa, U, and Guastafierro, Salvatore

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results